Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 3/20 | 0.30 |
| ▸ | PPARA | Q07869 | 3/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22823984 | 1.00 | GAA (0.33) | GAAPOLBMAPK1MKNK2MAPT | |
| SCHEMBL29365366 | 0.88 | PPARG (0.38) | GAAPOLBPPARGPPARASMN1; SMN2 | |
| SCHEMBL22823983 | 0.88 | PPARG (0.38) | GAAPOLBPPARGPPARASMN1; SMN2 | |
| SCHEMBL28687049 | 0.88 | PPARG (0.38) | GAAPOLBPPARGPPARASMN1; SMN2 | |
| SCHEMBL29602077 | 0.86 | AAK1 (0.34) | MKNK2MAPT | |
| SCHEMBL22823750 | 0.86 | AAK1 (0.34) | MKNK2MAPT | |
| SCHEMBL22823973 | 0.82 | PPARG (0.38) | PPARGPPARA | |
| SCHEMBL22823920 | 0.82 | PPOX (0.39) | GAAPOLBMAPK1MAPTTSHR | |
| SCHEMBL28676544 | 0.82 | PPARG (0.38) | PPARGPPARA | |
| SCHEMBL29367873 | 0.82 | PPARG (0.38) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415771-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2025-09-16 | — | — | US | disclosed |
| CN-114008012-B | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-3986852-B1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2024-10-16 | — | — | EP | disclosed |
| US-20220388938-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2022-12-08 | — | — | US | disclosed |
| EP-3986852-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388938-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | RYR1, CACNB1, SMN1; SMN2 | GAA 2442/4885POLB 4142/4885MAPK1 2692/4885 |
| US-12415771-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, SMN1; SMN2 | GAA 2442/4885POLB 4142/4885MAPK1 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.